StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
99
This month
1
This week
1
This year
10
Publishing Date
2023 - 09 - 26
2
2023 - 09 - 05
2
2023 - 05 - 22
1
2023 - 05 - 04
1
2023 - 04 - 24
1
2023 - 04 - 19
1
2023 - 04 - 12
1
2023 - 04 - 11
1
2023 - 04 - 10
1
2023 - 04 - 06
1
2023 - 04 - 03
1
2023 - 03 - 22
1
2023 - 03 - 16
1
2023 - 03 - 08
1
2023 - 03 - 07
1
2023 - 03 - 01
1
2023 - 01 - 26
1
2023 - 01 - 19
1
2023 - 01 - 11
1
2022 - 12 - 14
1
2022 - 11 - 28
1
2022 - 10 - 31
1
2022 - 10 - 06
1
2022 - 09 - 30
1
2022 - 09 - 29
1
2022 - 08 - 15
1
2022 - 08 - 04
1
2022 - 06 - 28
1
2022 - 06 - 16
1
2022 - 04 - 27
1
2022 - 04 - 26
1
2022 - 04 - 12
1
2022 - 03 - 23
1
2022 - 03 - 08
1
2022 - 03 - 07
1
2022 - 02 - 22
1
2022 - 01 - 26
1
2022 - 01 - 24
1
2021 - 12 - 14
1
2021 - 11 - 18
1
2021 - 10 - 25
1
2021 - 09 - 07
1
2021 - 08 - 09
1
2021 - 07 - 07
1
2021 - 07 - 02
1
2021 - 06 - 30
1
2021 - 06 - 29
1
2021 - 06 - 08
1
2021 - 06 - 04
1
2021 - 05 - 12
1
2021 - 04 - 15
1
2021 - 04 - 06
1
2021 - 03 - 26
1
2021 - 03 - 25
1
2021 - 03 - 17
1
2021 - 03 - 15
1
2021 - 03 - 08
1
2021 - 02 - 10
2
2020 - 12 - 08
1
2020 - 12 - 01
1
Sector
Health technology
3
Professional, scientific, and technical services
99
Tags
Acquisition
1
Agreement
2
Alliances
1
Als
1
America
1
Approval
1
Asco
1
Aspire
7
Association
3
Australia
1
Biomidwest
20
Biopharma
1
Business
5
Cancer
13
Car-t
2
Cel
1
Cell
4
China
1
Clinical hold
1
Clinical-trials-phase-ii
1
Collaboration
4
Conference
17
Designation
2
Diabetes
4
Ema
2
Endocrine
2
Europe
2
Events
2
Financial
6
Financial results
6
Gemcitabine
9
Immunology
2
Meeting
2
Metabolic
2
Million
3
N/a
70
Offering
9
Ovarian cancer
2
Pancreas
2
Pancreatic
11
Patent
9
Phase 1
2
Phase 1b
3
Phase 2b
3
Positive
2
Potential
5
Pre-clinical
2
Preclinical
3
Presentation
12
Program
2
Publication
5
Report
3
Research
7
Results
14
Sbp-101
22
Therapeutics
8
Therapy
3
Trial
18
Update
6
Year
2
Entities
Acumen pharmaceuticals inc
52
Acurx pharmaceuticals llc
55
Akoya biosciences inc
78
Alzamend neuro inc
44
Biomea fusion inc
89
Biorestorative therapies, inc.
55
Bioxytran, inc
41
Briacell therapeutics corp.
100
Century therapeutics inc
48
Clinuvel pharmaceuticals ltd
110
Compass therapeutics inc
35
Connect biopharma holdings ltd - adr
36
Cyclo therapeutics inc - class a
67
Day one biopharmaceuticals inc
49
Definitive healthcare corp.
45
Elevation oncology inc
41
Endonovo therapeutics, inc.
32
Entrada therapeutics inc
34
Finch therapeutics group inc
35
First advantage corp.
45
Gain therapeutics inc
69
Genedx holdings corp - class a
42
Hive blockchain technologies ltd.
35
Icoreconnect inc.
36
Immunoprecise antibodies ltd
84
Impel neuropharma inc.
38
Instil bio inc
31
Intertek group plc
157
Ispecimen inc
62
Legalzoom.com inc.
34
Lianbio - adr
47
Lonza group ag
95
Medicine man technologies, inc.
31
Miromatrix medical inc
47
Mister car wash inc
35
Molecular partners ag - adr
61
Monte rosa therapeutics inc
42
Morgan stanley
45
Omniq corp
110
Panbela therapeutics inc
99
Prometheus biosciences inc
35
Pyxis oncology inc
45
Quoin pharmaceuticals ltd - adr
47
Recursion pharmaceuticals inc - class a
53
Reneo pharmaceuticals inc
50
Sage group plc
74
Sap se
49
Seer inc - class a
49
Singular genomics systems inc
41
Sunshine biopharma, inc
33
Thermo fisher scientific inc
59
Transcode therapeutics inc
74
Tscan therapeutics inc
73
Unicycive therapeutics inc
41
Uphealth inc
52
Vectivbio holding ag
60
Vera therapeutics inc - class a
60
Verve therapeutics inc
40
Werewolf therapeutics inc
45
Xilio therapeutics inc
37
Symbols
PBLA
99
SNY
3
SNYNF
3
Exchanges
Nasdaq
99
Crawled Date
2023 - 09 - 26
2
2023 - 09 - 05
2
2023 - 05 - 22
1
2023 - 05 - 04
1
2023 - 04 - 24
1
2023 - 04 - 19
1
2023 - 04 - 12
1
2023 - 04 - 11
1
2023 - 04 - 10
1
2023 - 04 - 06
1
2023 - 04 - 03
1
2023 - 03 - 22
1
2023 - 03 - 16
1
2023 - 03 - 08
1
2023 - 03 - 07
1
2023 - 03 - 01
1
2023 - 01 - 26
1
2023 - 01 - 19
1
2023 - 01 - 11
1
2022 - 12 - 14
1
2022 - 11 - 28
1
2022 - 10 - 31
1
2022 - 10 - 06
1
2022 - 09 - 30
1
2022 - 09 - 29
1
2022 - 08 - 15
1
2022 - 08 - 04
1
2022 - 06 - 28
1
2022 - 06 - 16
1
2022 - 04 - 27
1
2022 - 04 - 26
1
2022 - 04 - 12
1
2022 - 03 - 23
1
2022 - 03 - 08
1
2022 - 03 - 07
1
2022 - 02 - 22
1
2022 - 01 - 26
1
2022 - 01 - 24
1
2021 - 12 - 14
1
2021 - 11 - 18
1
2021 - 10 - 25
1
2021 - 09 - 07
1
2021 - 08 - 09
1
2021 - 07 - 07
1
2021 - 07 - 02
1
2021 - 06 - 30
1
2021 - 06 - 29
1
2021 - 06 - 08
1
2021 - 06 - 04
1
2021 - 05 - 12
1
2021 - 04 - 15
1
2021 - 04 - 06
1
2021 - 03 - 26
1
2021 - 03 - 25
1
2021 - 03 - 17
1
2021 - 03 - 15
1
2021 - 03 - 08
1
2021 - 02 - 10
2
2020 - 12 - 08
1
2020 - 12 - 01
1
Crawled Time
05:00
1
10:00
1
12:00
16
12:01
1
12:20
11
13:00
19
13:03
1
13:04
1
13:20
3
13:35
1
14:00
10
14:15
1
14:20
1
15:00
2
15:30
1
16:00
1
16:01
1
17:00
3
18:00
2
19:00
2
20:00
9
21:00
5
22:00
4
23:00
2
Source
www.biospace.com
29
www.globenewswire.com
70
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
sector :
Professional, scientific, and technical services
entities :
Panbela therapeutics inc
save search
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial's lower-than-expected event rate suggests improved survival outcomes
Published:
2024-04-22
(Crawled : 13:00)
- biospace.com/
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
0.0%
|
O:
-4.76%
H:
17.5%
C:
17.5%
aspire
for
trial
therapeutics
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Published:
2024-03-26
(Crawled : 20:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-34.38%
|
O:
6.25%
H:
0.59%
C:
-0.76%
business
update
financial
results
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Published:
2024-03-12
(Crawled : 20:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
Email alert
Add to watchlist
conference
year
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
Published:
2024-02-15
(Crawled : 13:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-69.12%
|
O:
2.94%
H:
0.71%
C:
-9.29%
nasdaq
Panbela Announces Closing of Approximately $9.0 Million Public Offering
Published:
2024-02-01
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-69.78%
|
O:
0.0%
H:
0.0%
C:
-9.35%
million
offering
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Published:
2024-01-30
(Crawled : 13:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-71.62%
|
O:
2.03%
H:
0.66%
C:
-11.26%
sbp-101
association
presentation
cancer
research
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
Published:
2024-01-29
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-90.16%
|
O:
-64.4%
H:
1.97%
C:
-2.63%
million
offering
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
Published:
2024-01-25
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-88.49%
|
O:
2.47%
H:
0.94%
C:
-13.1%
momentum
pancreatic
aspire
trial
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Published:
2024-01-18
(Crawled : 13:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-95.16%
|
O:
-5.49%
H:
0.0%
C:
-18.9%
publication
trial
therapy
study
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
Published:
2024-01-16
(Crawled : 13:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-96.67%
|
O:
-12.7%
H:
0.0%
C:
-13.95%
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
Published:
2023-12-21
(Crawled : 14:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-98.25%
|
O:
-17.5%
H:
10.1%
C:
-12.22%
million
therapeutics
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
Published:
2023-12-18
(Crawled : 13:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-95.41%
|
O:
29.1%
H:
177.92%
C:
71.16%
approval
therapeutics
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
Published:
2023-12-04
(Crawled : 13:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-96.49%
|
O:
-3.96%
H:
0.0%
C:
-9.72%
sbp-101
publication
cell
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
Published:
2023-11-29
(Crawled : 13:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-95.87%
|
O:
6.5%
H:
19.9%
C:
-8.43%
continuation
review
aspire
trial
Panbela Provides Business Update and Reports Q3 2023 Financial Results
Published:
2023-11-09
(Crawled : 21:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
2.81%
|
O:
-1.28%
H:
0.0%
C:
0.0%
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-96.39%
|
O:
6.53%
H:
0.0%
C:
-3.63%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
1.84%
|
O:
-0.32%
H:
0.0%
C:
0.0%
business
update
financial
results
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
Published:
2023-11-03
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-97.79%
|
O:
-27.19%
H:
11.96%
C:
4.12%
therapeutics
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
Published:
2023-11-02
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-97.36%
|
O:
46.89%
H:
5.97%
C:
-18.8%
publication
cell
preclinical
diabetes
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
Published:
2023-10-31
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-97.32%
|
O:
15.94%
H:
1.1%
C:
-10.11%
sbp-101
patent
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
Published:
2023-10-25
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-97.53%
|
O:
-5.57%
H:
5.83%
C:
5.1%
publication
car-t
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
Published:
2023-10-24
(Crawled : 12:00)
- globenewswire.com
PBLA
|
News
|
$0.4748
-6.31%
20K
|
Professional, Scientific, and T...
|
-97.45%
|
O:
-0.6%
H:
3.66%
C:
3.6%
conference
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.